212 related articles for article (PubMed ID: 23407549)
21. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
[TBL] [Abstract][Full Text] [Related]
22. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
23. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
25. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
26. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
[TBL] [Abstract][Full Text] [Related]
27. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
[TBL] [Abstract][Full Text] [Related]
28. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.
Spencer DH; Young MA; Lamprecht TL; Helton NM; Fulton R; O'Laughlin M; Fronick C; Magrini V; Demeter RT; Miller CA; Klco JM; Wilson RK; Ley TJ
Leukemia; 2015 Jun; 29(6):1279-89. PubMed ID: 25600023
[TBL] [Abstract][Full Text] [Related]
29. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
[TBL] [Abstract][Full Text] [Related]
30. Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene.
Ishibashi M; Yokosuka T; Yanagimachi MD; Iwasaki F; Tsujimoto SI; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Kajiwara R; Tanaka F; Goto H; Yokota S
Turk J Haematol; 2016 Dec; 33(4):331-334. PubMed ID: 27094503
[TBL] [Abstract][Full Text] [Related]
31. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.
de Rooij JD; Hollink IH; Arentsen-Peters ST; van Galen JF; Berna Beverloo H; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Zimmermann M; Alonzo TA; Pieters R; Meshinchi S; van den Heuvel-Eibrink MM; Zwaan CM
Leukemia; 2013 Dec; 27(12):2280-8. PubMed ID: 23531517
[TBL] [Abstract][Full Text] [Related]
32. [Genetic aberrations and new treatment strategies for pediatric acute myeloid leukemia].
Shiba N
Rinsho Ketsueki; 2018; 59(10):2260-2267. PubMed ID: 30305534
[TBL] [Abstract][Full Text] [Related]
33. Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy.
Smith SM; Lee A; Tong S; Leung S; Hongo H; Rivera J; Sweet-Cordero A; Michlitsch J; Stieglitz E
Cold Spring Harb Mol Case Stud; 2022 Aug; 8(5):. PubMed ID: 35927023
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
35. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Sun SM; Rockova V; Bullinger L; Dijkstra MK; Döhner H; Löwenberg B; Jongen-Lavrencic M
Leukemia; 2013 Jan; 27(1):100-6. PubMed ID: 22692398
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
37. Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards.
Al-Kzayer LF; Uyen le TN; Al-Jadiry MF; Al-Hadad SA; Al-Badri SA; Ghali HH; Ameen NA; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Al-Ani MH; Saber PA; Khalil HM; Inoshita T; Kamata M; Koike K; Sakashita K
Ann Hematol; 2014 Jun; 93(6):949-55. PubMed ID: 24464319
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
[TBL] [Abstract][Full Text] [Related]
39. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.
Zhang TJ; Zhou JD; Ma JC; Deng ZQ; Qian Z; Yao DM; Yang J; Li XX; Lin J; Qian J
Clin Chem Lab Med; 2017 Jan; 55(1):123-131. PubMed ID: 27305704
[TBL] [Abstract][Full Text] [Related]
40. Type J CBFbeta/MYH11 transcript in the M4Eo subtype of acute myeloid leukemia.
Trnková Z; Peková S; Bedrlíková R; Záková D; Zemanová Z; Polák J; Michalová K; Cermák J; Schwarz J
Hematology; 2003 Apr; 8(2):115-7. PubMed ID: 12745661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
